Table 4.
Patient beliefs about PCSK9 inhibitors by use status*
| Patient beliefs | Overall (n=520) |
On therapy with approval (n=406) |
Discontinued/did not initiate with approval (n=114) |
p-value |
|---|---|---|---|---|
| Drug effectiveness | ||||
| Confidence in drug treating condition | <0.0001 | |||
| Not at all confident | 6 (1.2%) | 0 (0.0%) | 6 (6.0%) | |
| A little confident | 8 (1.6%) | 6 (1.5%) | 2 (2.0%) | |
| Somewhat confident | 37 (7.5%) | 29 (7.4%) | 8 (8.0%) | |
| Quite confident | 85 (17.3%) | 68 (17.4%) | 17 (17.0%) | |
| Very confident | 355 (72.3%) | 288 (73.7%) | 67 (67.0%) | |
| Injection effectiveness in treating condition | 0.003 | |||
| Not at all effective | 5 (1.2%) | 1 (0.3%) | 4 (4.1%) | |
| A little effective | 8 (1.8%) | 4 (1.2%) | 4 (4.1%) | |
| Somewhat effective | 26 (6.0%) | 19 (5.6%) | 7 (7.2%) | |
| Quite effective | 68 (15.7%) | 49 (14.5%) | 19 (19.6%) | |
| Very effective | 327 (75.4%) | 264 (78.3%) | 63 (65.0%) | |
| Drug safety | ||||
| Acceptability of side effects | <0.0001 | |||
| Very unacceptable | 42 (8.6%) | 18 (4.7%) | 24 (23.1%) | |
| Unacceptable | 18 (3.7%) | 4 (1.0%) | 14 (13.5%) | |
| Neither acceptable nor unacceptable | 53 (10.8%) | 45 (11.7%) | 8 (7.7%) | |
| Acceptable | 114 (23.3%) | 94 (24.4%) | 20 (19.2%) | |
| Very acceptable | 262 (53.6%) | 224 (58.2%) | 38 (36.5%) | |
| Drug delivery | ||||
| Acceptability of pain at injection site | 0.009 | |||
| Very unacceptable | 19 (3.8%) | 15 (3.7%) | 4 (3.9%) | |
| Unacceptable | 9 (1.8%) | 3 (0.8%) | 6 (5.9%) | |
| Neither acceptable nor unacceptable | 45 (9.0%) | 35 (8.7%) | 10 (9.8%) | |
| Acceptable | 131 (26.0%) | 102 (25.4%) | 29 (28.4%) | |
| Very acceptable | 299 (59.4%) | 246 (61.4%) | 53 (52.0%) | |
| Confidence in ability to give injection | 0.01 | |||
| Not at all confident | 3 (0.6%) | 3 (0.8%) | 0 (0.0%) | |
| A little confident | 5 (1.0%) | 4 (1.0%) | 1 (1.0%) | |
| Somewhat confident | 13 (2.6%) | 11 (2.8%) | 2 (2.0%) | |
| Quite confident | 59 (11.8%) | 37 (9.3%) | 22 (21.6%) | |
| Very confident | 422 (84.1%) | 345 (86.3%) | 77 (75.5%) | |
| Ease of giving injection | 0.17 | |||
| Very difficult | 1 (0.2%) | 1 (0.3%) | 0 (0.0%) | |
| Difficult | 8 (1.6%) | 6 (1.5%) | 2 (2.0%) | |
| Neither difficult nor easy | 27 (5.4%) | 25 (6.2%) | 2 (2.0%) | |
| Easy | 86 (17.1%) | 62 (15.5%) | 24 (23.5%) | |
| Very easy | 381 (75.8%) | 307 (76.6%) | 74 (72.6%) | |
| Drug acceptability | ||||
| Overall acceptability of treatment | 0.0001 | |||
| Very unacceptable | 15 (3.0%) | 9 (2.3%) | 6 (5.7%) | |
| Unacceptable | 6 (1.2%) | 1 (0.3%) | 5 (4.8%) | |
| Neither acceptable nor unacceptable | 19 (3.8%) | 14 (3.5%) | 5 (4.8%) | |
| Acceptable | 98 (19.4%) | 72 (18.1%) | 26 (24.8%) | |
| Very acceptable | 366 (72.6%) | 303 (75.9%) | 63 (60.0%) | |
*
Email survey only
PCSK9, proprotein convertase subtilisin/kexin type 9 inhibitors